Sunshine Biopharma closes $2.46M registered direct offering of common stock and pre-funded warrants

Sunshine Biopharma Inc.

Gross proceeds of approximately $2.46M from sale of 1,188,404 shares of common stock (or pre-funded warrants) at $2.07 per share.
Net proceeds of approximately $1.8M after deducting offering expenses; funds to be used for general corporate purposes and working capital.
Pre-funded warrants exercisable immediately at $0.001 per share; expire when exercised in full.
Offering closed on April 3, 2025; Aegis Capital acted as exclusive placement agent.
Pricing was at the market under Nasdaq rules; shelf registration statement effective January 15, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.